JP2024540275A5 - - Google Patents
Info
- Publication number
- JP2024540275A5 JP2024540275A5 JP2024526511A JP2024526511A JP2024540275A5 JP 2024540275 A5 JP2024540275 A5 JP 2024540275A5 JP 2024526511 A JP2024526511 A JP 2024526511A JP 2024526511 A JP2024526511 A JP 2024526511A JP 2024540275 A5 JP2024540275 A5 JP 2024540275A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- car
- cells
- response
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163275471P | 2021-11-04 | 2021-11-04 | |
| CNPCT/CN2021/128578 | 2021-11-04 | ||
| US63/275,471 | 2021-11-04 | ||
| PCT/CN2021/128578 WO2023077343A1 (en) | 2021-11-04 | 2021-11-04 | Bcma-targeted car-t cell therapy for multiple myeloma |
| PCT/US2022/079216 WO2023081752A1 (en) | 2021-11-04 | 2022-11-03 | Bcma-targeted car-t cell therapy for multiple myeloma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024540275A JP2024540275A (ja) | 2024-10-31 |
| JP2024540275A5 true JP2024540275A5 (https=) | 2025-11-11 |
Family
ID=84370104
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024526511A Pending JP2024540275A (ja) | 2021-11-04 | 2022-11-03 | Ｂｃｍａを標的とする、多発性骨髄腫のためのｃａｒ－ｔ細胞療法関連出願の相互参照 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230277589A1 (https=) |
| EP (1) | EP4426737A1 (https=) |
| JP (1) | JP2024540275A (https=) |
| KR (1) | KR20240117530A (https=) |
| CN (1) | CN118510801A (https=) |
| AU (1) | AU2022381186A1 (https=) |
| CA (1) | CA3237341A1 (https=) |
| IL (1) | IL312602A (https=) |
| JO (1) | JOP20240104A1 (https=) |
| MX (1) | MX2024005461A (https=) |
| WO (1) | WO2023081752A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021091945A1 (en) | 2019-11-05 | 2021-05-14 | Janssen Biotech, Inc. | Bcma-targeted car-t cell therapy of multiple myeloma |
| WO2025006799A1 (en) | 2023-06-27 | 2025-01-02 | Capstan Therapeutics, Inc. | Extracorporeal and ex vivo engineering of select cell populations from peripheral blood |
| WO2025076341A1 (en) * | 2023-10-05 | 2025-04-10 | Janssen Biotech, Inc. | Improved methods in lentiviral manufacturing for production of car-t cell drug products |
| US20250144234A1 (en) | 2023-11-02 | 2025-05-08 | Capstan Therapeutics Inc. | RNA for In vivo Transfection with Increased Expression |
| WO2025170902A1 (en) * | 2024-02-05 | 2025-08-14 | Legend Biotech Usa Inc. | Bcma-targeted car-t cell therapy for multiple myeloma |
| WO2026072671A1 (en) | 2024-09-24 | 2026-04-02 | City Of Hope | Methods comprising oncolytic viruses expressing bcmat and bcma-targeted therapies |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| IE913929A1 (en) | 1990-11-13 | 1992-05-20 | Immunex Corp | Bifunctional selectable fusion genes |
| AU6953394A (en) | 1993-05-21 | 1994-12-20 | Targeted Genetics Corporation | Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene |
| US5814618A (en) | 1993-06-14 | 1998-09-29 | Basf Aktiengesellschaft | Methods for regulating gene expression |
| US5464758A (en) | 1993-06-14 | 1995-11-07 | Gossen; Manfred | Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters |
| US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
| US5885827A (en) | 1996-01-23 | 1999-03-23 | The Regents Of The Universtiy Of California | Eukaryotic high rate mutagenesis system |
| US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
| WO2001058479A1 (en) | 2000-02-08 | 2001-08-16 | The Penn State Research Foundation | Immunotherapy using interleukin 13 receptor subunit alpha 2 |
| FR2814642B1 (fr) | 2000-10-03 | 2005-07-01 | Ass Pour Le Dev De La Rech En | Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee |
| ES2971647T3 (es) | 2005-04-15 | 2024-06-06 | Macrogenics Inc | Diacuerpos covalentes y usos de los mismos |
| US9963510B2 (en) | 2005-04-15 | 2018-05-08 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| US20090075378A1 (en) | 2007-02-20 | 2009-03-19 | Anaptysbio, Inc. | Somatic hypermutation systems |
| WO2018028647A1 (en) | 2016-08-10 | 2018-02-15 | Legend Biotech Usa Inc. | Chimeric antigen receptors targeting bcma and methods of use thereof |
| CN105384825B (zh) | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
| US20220177524A1 (en) * | 2018-07-26 | 2022-06-09 | Nanjing Legend Biotech Co., Ltd. | Nef-containing t cells and methods of producing thereof |
-
2022
- 2022-11-03 IL IL312602A patent/IL312602A/en unknown
- 2022-11-03 US US18/052,349 patent/US20230277589A1/en active Pending
- 2022-11-03 KR KR1020247015027A patent/KR20240117530A/ko active Pending
- 2022-11-03 JP JP2024526511A patent/JP2024540275A/ja active Pending
- 2022-11-03 CA CA3237341A patent/CA3237341A1/en active Pending
- 2022-11-03 WO PCT/US2022/079216 patent/WO2023081752A1/en not_active Ceased
- 2022-11-03 CN CN202280073251.5A patent/CN118510801A/zh active Pending
- 2022-11-03 MX MX2024005461A patent/MX2024005461A/es unknown
- 2022-11-03 EP EP22817497.5A patent/EP4426737A1/en active Pending
- 2022-11-03 AU AU2022381186A patent/AU2022381186A1/en active Pending
-
2024
- 2024-04-30 JO JOJO/P/2024/0104A patent/JOP20240104A1/ar unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024540275A5 (https=) | ||
| US20250262318A1 (en) | Methods and pharmaceutical composition for the treatment of cancer | |
| CN112384534A (zh) | 用于增强nk细胞对靶细胞的杀死的组合物和方法 | |
| JP2022513420A5 (https=) | ||
| EP3880231A1 (en) | Method of treating a tumor with a combination of il-7 protein and an immune checkpoint inhibitor | |
| JP2023500338A5 (https=) | ||
| WO2012007576A1 (en) | Superior efficacy of cd37 antibodies in cll blood samples | |
| JP2025175307A (ja) | 逐次抗ｃｄ１９治療 | |
| JP2021525067A5 (https=) | ||
| US20250099542A1 (en) | Method of treating a tumor with a combination of il-7 protein and vegf antagonist | |
| CN119095869A (zh) | 用于预防和/或治疗炎症性病症的靶向共刺激分子的具有嵌合抗原受体的调节性t细胞 | |
| US20240139241A1 (en) | Compositions and methods for conditioning patients for cell therapy | |
| CN119013309A (zh) | 靶向pd-l1和cd40的抗原结合蛋白及其制备和应用 | |
| TW202302642A (zh) | 用於治療抗體介導移植物排斥用途之抗ｃｄ３８抗體 | |
| Aldeghaither | Identifying Molecular Mechanisms of Resistance to Antibody Dependent Cell Mediated Cytotoxicity (ADCC) | |
| US20230190804A1 (en) | Compositions and methods for augmenting chimeric antigen receptor (car) t cell therapies | |
| CN120302979A (zh) | 针对CD40和CD137的多特异性抗体与抗PD1 Ab和化学治疗的组合治疗 | |
| TW202611075A (zh) | 以雙特異性BCMAxCD3抗體治療輕鏈類澱粉變性症之方法 | |
| EA048837B1 (ru) | Ступенчатая анти-cd19 терапия | |
| JP2024540320A5 (https=) | ||
| IL256261A (en) | Compounds and method for hide1 |